Compare FIBK & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | APGE |
|---|---|---|
| Founded | 1879 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.7B |
| IPO Year | 2010 | 2023 |
| Metric | FIBK | APGE |
|---|---|---|
| Price | $35.16 | $76.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $35.17 | ★ $100.00 |
| AVG Volume (30 Days) | ★ 2.1M | 757.0K |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 5.31% | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | ★ 2.37 | N/A |
| Revenue | ★ $953,700,000.00 | N/A |
| Revenue This Year | $9.24 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $14.94 | ★ N/A |
| Revenue Growth | ★ 0.26 | N/A |
| 52 Week Low | $22.95 | $26.20 |
| 52 Week High | $36.05 | $78.12 |
| Indicator | FIBK | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 72.83 |
| Support Level | $32.47 | $74.00 |
| Resistance Level | $36.05 | $76.87 |
| Average True Range (ATR) | 0.80 | 3.40 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 83.25 | 87.77 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.